tiprankstipranks
Trending News
More News >
Nova Leap Health (TSE:NLH)
:NLH
Canadian Market

Nova Leap Health (NLH) AI Stock Analysis

Compare
11 Followers

Top Page

TS

Nova Leap Health

(NLH)

Rating:72Outperform
Price Target:
C$0.50
▲( 85.19% Upside)
Nova Leap Health exhibits a balanced profile with key strengths in technical momentum and positive corporate events, such as strategic acquisitions and strong shareholder support. Financial performance and valuation remain areas for improvement, given revenue challenges and fair valuation metrics.

Nova Leap Health (NLH) vs. iShares MSCI Canada ETF (EWC)

Nova Leap Health Business Overview & Revenue Model

Company DescriptionNova Leap Health Corp. provides home and home health care services in the United States and Canada. Its services include dementia care, companionship, personal and respite care, cooking and meal preparation, bathing, dressing, grooming, housekeeping, errands, transportation, and medication reminders by nursing staff. Nova Leap Health Corp. was incorporated in 2015 and is headquartered in Halifax, Canada.
How the Company Makes MoneyNova Leap Health makes money by acquiring and operating home health care businesses that provide services such as personal care, companionship, and assistance with daily living activities. The company's revenue model is based on a fee-for-service structure, where they charge clients or their families for the home care services provided. Additionally, Nova Leap Health may receive payments from government programs, insurance companies, or other third-party payers, depending on the region and specific client circumstances. Strategic acquisitions of underperforming or undervalued home care businesses allow Nova Leap Health to expand its market presence and increase revenue streams, leveraging economies of scale and operational efficiencies to enhance profitability.

Nova Leap Health Financial Statement Overview

Summary
Nova Leap Health exhibits a mixed financial performance with signs of profitability improvement in 2024, supported by a strong equity position and low leverage. While revenue growth poses challenges, the company shows potential in operational efficiency and cash flow management.
Income Statement
67
Positive
Nova Leap Health has demonstrated fluctuations in revenue with a notable decline from $28.2M in 2022 to $25.8M in 2024. Gross profit margin has remained relatively stable, yet net income turned positive in 2024 at $1.38M from a loss in previous years, indicating improved profitability. EBIT and EBITDA margins are positive but show room for enhancement, highlighting potential operational efficiency improvements.
Balance Sheet
72
Positive
The company maintains a healthy equity base with an equity ratio of approximately 81.5% in 2024. The debt-to-equity ratio is relatively low at 0.14, suggesting manageable leverage. Return on equity improved significantly in 2024, reflecting enhanced profitability and effective use of equity.
Cash Flow
60
Neutral
Operating cash flow decreased to $1.39M in 2024 from $2.15M in 2023, reflecting potential challenges in cash generation from operations. However, the company maintains positive free cash flow. The operating cash flow to net income ratio is strong at 1.01, indicating efficient conversion of income to cash.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
25.76M26.18M28.21M21.28M17.31M
Gross Profit
9.89M9.77M9.98M7.21M5.87M
EBIT
863.71K460.15K-1.10M3.89M1.81M
EBITDA
2.50M994.47K420.35K4.76M2.36M
Net Income Common Stockholders
1.38M-1.05M-835.75K1.76M1.26M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.40M894.76K1.27M1.73M2.78M
Total Assets
22.39M20.90M23.95M26.77M17.54M
Total Debt
2.53M1.40M3.97M6.20M5.96M
Net Debt
1.12M503.65K2.69M4.47M3.18M
Total Liabilities
4.14M2.70M5.27M8.29M7.69M
Stockholders Equity
18.25M18.20M18.68M18.48M9.84M
Cash FlowFree Cash Flow
1.36M2.13M949.49K2.18M3.01M
Operating Cash Flow
1.39M2.15M1.02M2.18M3.01M
Investing Cash Flow
-1.59M-23.13K-56.24K-7.40M-1.56M
Financing Cash Flow
729.78K-2.52M-1.41M4.33M-325.46K

Nova Leap Health Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.27
Price Trends
50DMA
0.25
Positive
100DMA
0.25
Positive
200DMA
0.26
Positive
Market Momentum
MACD
<0.01
Negative
RSI
57.92
Neutral
STOCH
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NLH, the sentiment is Positive. The current price of 0.27 is above the 20-day moving average (MA) of 0.26, above the 50-day MA of 0.25, and above the 200-day MA of 0.26, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.92 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NLH.

Nova Leap Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
TSNLH
72
Outperform
C$23.57M20.454.53%4.09%
65
Neutral
C$186.31M-4.48%-0.69%8.08%
53
Neutral
$5.14B3.03-44.09%2.83%16.75%-0.06%
C$13.86M
$150.51K
$189.99M
TSPHA
54
Neutral
C$3.89M-239.50%3.03%-410.90%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:NLH
Nova Leap Health
0.27
-0.05
-15.62%
TSE:CRRX
CareRx
2.96
0.90
43.69%
TSE:NUMI
Numinus Wellness
0.04
-0.03
-42.86%
JNHMF
Jack Nathan Medical
0.03
0.00
0.00%
TSE:MEDI
Wellbeing Digital Sciences Inc
1.85
0.00
0.00%
TSE:PHA
Premier Health of America Inc
0.07
-0.25
-78.13%

Nova Leap Health Corporate Events

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Nova Leap Health Corp’s Shareholders Approve Key Business Items at Annual Meeting
Positive
May 23, 2025

Nova Leap Health Corp announced that all items of business were approved at their annual and special meeting of shareholders, including the election of six board members and the re-appointment of their auditor. Additionally, the company’s 10% rolling equity incentive plan was ratified, reflecting strong shareholder support and potentially impacting the company’s strategic initiatives and stakeholder interests.

The most recent analyst rating on (TSE:NLH) stock is a Buy with a C$0.60 price target. To see the full list of analyst forecasts on Nova Leap Health stock, see the TSE:NLH Stock Forecast page.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Nova Leap Health Corp. Reports Q1 2025 Financial Results and Strategic Expansions
Neutral
May 8, 2025

Nova Leap Health Corp. reported a 7.7% increase in Q1 2025 revenues compared to Q4 2024, although Adjusted EBITDA decreased by 30%. The company made strategic acquisitions in Nova Scotia, contributing to its fastest-growing segment, and opened a new office in Kentucky. Despite a net loss in Q1, the company expects record revenues in Q2, driven by recent investments and acquisitions.

M&A TransactionsBusiness Operations and Strategy
Nova Leap Health Expands with Nova Scotia Acquisition
Positive
May 6, 2025

Nova Leap Health Corp. has completed the acquisition of a home care services company in Nova Scotia for $390,000, funded with cash on hand. This acquisition is part of Nova Leap’s strategy to expand its market presence in Nova Scotia, enhancing its operations and potentially benefiting stakeholders by increasing its service capacity in the region.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.